Entera Bio Ltd.
ENTXNext catalyst
No upcoming catalyst in our data
No upcoming FDA decision, filing or trial readout is on file for ENTX. That does not mean none is planned.
Get an email about ENTX's next catalysts
Track Entera Bio (ENTX) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.
1 upcoming event in our data (earnings).See the timeline
1 upcoming, 0 past
ENTX Earnings Report
Date estimated from past reporting pattern, not yet confirmed by the company | FQ end Sep/2026 | Call: tbd
Market Overview
Stock performance and key metrics
EB612 (EBP05)
Hypoparathyroidism
EBP05
Hypoparathyroidism
EnteraBio's Oral Parathyroid Hormone (1-34)
Hypoparathyroidism
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
EB612 (EBP05) | Phase 2 | Hypoparathyroidism | - | - |
EBP05 | Phase 2 | Hypoparathyroidism | - | - |
EnteraBio's Oral Parathyroid Hormone (1-34) | Phase 2 | Hypoparathyroidism | - | - |
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Frequently asked questions
What is in Entera Bio Ltd.'s drug pipeline?→
CatalystAlert tracks 3 drug candidates in Entera Bio Ltd.'s (ENTX) pipeline across Phase 2. Its lead program is EB612 (EBP05) (Phase 2). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Entera Bio Ltd.'s next FDA catalyst?→
CatalystAlert tracks every upcoming catalyst for Entera Bio Ltd. (ENTX) — PDUFA decision dates, Phase 1/2/3 trial readouts, FDA advisory committee meetings and NDA/BLA filings — each confidence-rated as confirmed, estimated or AI-detected.
How do I track ENTX biotech catalysts?→
Add ENTX to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Entera Bio Ltd.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.